Two members of the WX8 family of PIKfyve inhibitors, WX8 and NDF, were tested for efficacy when treatment was initiated prior to infection with SARS-CoV-2 (B.1.351, “beta” variant, 1 × 105 plaque forming units [PFU]/mL) in Balb/c laboratory mice (Fig. 2a). This evidence concerns the gene PIKFYVE and infection.